FDA OKs New Therapy for Some Hemophilia Patients - NBC 10 Philadelphia
National & International News
The day’s top national and international news

FDA OKs New Therapy for Some Hemophilia Patients

Genentech, the drug's developer, says the list price will be about $482,000 for the first year and slightly less after that

    processing...

    NEWSLETTERS

    A Day in the Life of Penn Medicine
    AP/Genentech, Inc.
    This photo provided by Genentech, Inc. shows a package of the drug Hemlibra. On Thursday, Nov. 16, 2017, the Food and Drug Administration approved Hemlibra, the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia, an inherited blood-clotting disorder.

    U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia, an inherited blood-clotting disorder.

    The Food and Drug Administration on Thursday approved Hemlibra (hem-LEE'-bruh), a weekly injection for hemophilia A patients who have developed resistance to standard medicines.

    Genentech, the drug's developer, says the list price will be about $482,000 for the first year and slightly less after that.

    Genentech, a subsidiary of Swiss drugmaker Roche, says that's half the cost of the only other option for patients with this resistance. That treatment requires an IV drip several times a week.

    White Official Tells Black Woman He Belonged to Master Race

    [NATL] White Official Tells Black Woman He Belonged to Master Race

    Some Leavenworth County, Kansas, officials are calling for Commissioner Louis Klemp's resignation after he insulted a black woman who had just presented a land-use study to the commission. "I don't want you to think I am picking on you because we are part of the master race. You have a gap in your teeth. We are part of the master race, don't you forget that," Klemp said. 

    (Published Friday, Nov. 16, 2018)

    Hemophilia mostly affects males.